171 related articles for article (PubMed ID: 35315686)
1. Rifampin Pharmacokinetics/Pharmacodynamics in the Hollow-Fiber Model of Mycobacterium kansasii Infection.
Srivastava S; Boorgula GD; Wang JY; Huang HL; Howe D; Gumbo T; Heysell SK
Antimicrob Agents Chemother; 2022 Apr; 66(4):e0232021. PubMed ID: 35315686
[TBL] [Abstract][Full Text] [Related]
2. Isoniazid pharmacokinetics/pharmacodynamics as monotherapy and in combination regimen in the hollow fiber system model of Mycobacterium kansasii.
Boorgula GD; Singh S; Shankar P; Gumbo T; Heysell SK; Srivastava S
Tuberculosis (Edinb); 2023 Jan; 138():102289. PubMed ID: 36512853
[TBL] [Abstract][Full Text] [Related]
3. Clofazimine for the Treatment of Mycobacterium kansasii.
Srivastava S; Gumbo T
Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29844047
[No Abstract] [Full Text] [Related]
4. Omadacycline Pharmacokinetics/Pharmacodynamics in the Hollow Fiber System Model and Potential Combination Regimen for Short Course Treatment of Mycobacterium kansasii Pulmonary Disease.
Singh S; Gumbo T; Boorgula GD; Shankar P; Heysell SK; Srivastava S
Antimicrob Agents Chemother; 2022 Sep; 66(9):e0068722. PubMed ID: 35976006
[TBL] [Abstract][Full Text] [Related]
5. Rapid drug tolerance and dramatic sterilizing effect of moxifloxacin monotherapy in a novel hollow-fiber model of intracellular Mycobacterium kansasii disease.
Srivastava S; Pasipanodya J; Sherman CM; Meek C; Leff R; Gumbo T
Antimicrob Agents Chemother; 2015 Apr; 59(4):2273-9. PubMed ID: 25645830
[TBL] [Abstract][Full Text] [Related]
6. Treatment with a macrolide-containing regimen for Mycobacterium kansasii pulmonary disease.
Moon SM; Choe J; Jhun BW; Jeon K; Kwon OJ; Huh HJ; Lee NY; Daley CL; Koh WJ
Respir Med; 2019 Mar; 148():37-42. PubMed ID: 30827472
[TBL] [Abstract][Full Text] [Related]
7. Comparison of a Novel Regimen of Rifapentine, Tedizolid, and Minocycline with Standard Regimens for Treatment of Pulmonary Mycobacterium kansasii.
Chapagain M; Gumbo T; Heysell SK; Srivastava S
Antimicrob Agents Chemother; 2020 Sep; 64(10):. PubMed ID: 32690646
[TBL] [Abstract][Full Text] [Related]
8. An overview of drugs for the treatment of Mycobacterium kansasii pulmonary disease.
Srivastava S; Pasipanodya JG; Heysell SK; Boorgula GD; Gumbo T; McShane PJ; Philley JV
J Glob Antimicrob Resist; 2022 Mar; 28():71-77. PubMed ID: 34933140
[TBL] [Abstract][Full Text] [Related]
9. Drug resistance profile of Mycobacterium kansasii clinical isolates before and after 2-month empirical antimycobacterial treatment.
Zhang Y; Yu C; Jiang Y; Zheng X; Wang L; Li J; Shen X; Xu B
Clin Microbiol Infect; 2023 Mar; 29(3):353-359. PubMed ID: 36209990
[TBL] [Abstract][Full Text] [Related]
10. Nouveau short-course therapy and morphism mapping for clinical pulmonary
Srivastava S; Wang JY; Magombedze G; Chapagain M; Huang HL; Deshpande D; Heysell SK; Pasipanodya JG; Gumbo T
Antimicrob Agents Chemother; 2023 May; 95(5):. PubMed ID: 33558291
[TBL] [Abstract][Full Text] [Related]
11. Sarecycline pharmacokinetics/pharmacodynamics in the hollow-fibre model of Mycobacterium avium complex: so near and yet so far.
Singh S; Boorgula GD; Aryal S; Philley JV; Gumbo T; Srivastava S
J Antimicrob Chemother; 2024 Jan; 79(1):96-99. PubMed ID: 37946564
[TBL] [Abstract][Full Text] [Related]
12. Sulfonamide-containing regimens for disease caused by rifampin-resistant Mycobacterium kansasii.
Ahn CH; Wallace RJ; Steele LC; Murphy DT
Am Rev Respir Dis; 1987 Jan; 135(1):10-6. PubMed ID: 3800137
[TBL] [Abstract][Full Text] [Related]
13. Omadacycline pharmacokinetics/pharmacodynamics and efficacy against multidrug-resistant
Singh S; Gumbo T; Boorgula GD; Thomas TA; Philley JV; Srivastava S
Antimicrob Agents Chemother; 2024 Feb; 68(2):e0108023. PubMed ID: 38131673
[TBL] [Abstract][Full Text] [Related]
14. Long-term relapses after 12-month treatment for Mycobacterium kansasii lung disease.
Santin M; Dorca J; Alcaide F; Gonzalez L; Casas S; Lopez M; Guerra MR
Eur Respir J; 2009 Jan; 33(1):148-52. PubMed ID: 19118226
[TBL] [Abstract][Full Text] [Related]
15. Rifampin-resistant Mycobacterium kansasii.
Wallace RJ; Dunbar D; Brown BA; Onyi G; Dunlap R; Ahn CH; Murphy DT
Clin Infect Dis; 1994 May; 18(5):736-43. PubMed ID: 8075262
[TBL] [Abstract][Full Text] [Related]
16. Pulmonary Mycobacterium kansasii infection in Israel, 1999-2004: clinical features, drug susceptibility, and outcome.
Shitrit D; Baum GL; Priess R; Lavy A; Shitrit AB; Raz M; Shlomi D; Daniele B; Kramer MR
Chest; 2006 Mar; 129(3):771-6. PubMed ID: 16537880
[TBL] [Abstract][Full Text] [Related]
17. Treatment of pulmonary disease caused by Mycobacterium kansasii.
Huang HL; Lu PL; Lee CH; Chong IW
J Formos Med Assoc; 2020 Jun; 119 Suppl 1():S51-S57. PubMed ID: 32505588
[TBL] [Abstract][Full Text] [Related]
18. [Clinical characteristics and drug susceptibility test of nontuberculous mycobacterial lung disease].
Lou H; Sun Q; Gu J; Yang H; Hao XH; Xiao HP; Sha W
Zhonghua Jie He He Hu Xi Za Zhi; 2019 Dec; 42(12):901-906. PubMed ID: 31826533
[No Abstract] [Full Text] [Related]
19. Omadacycline drug susceptibility testing for non-tuberculous mycobacteria using oxyrase to overcome challenges with drug degradation.
Boorgula GD; Gumbo T; Singh S; McShane PJ; Philley JV; Srivastava S
Tuberculosis (Edinb); 2024 Jul; 147():102519. PubMed ID: 38754247
[TBL] [Abstract][Full Text] [Related]
20. Pulmonary Mycobacterium kansasii infection: comparison of the clinical features, treatment and outcome with pulmonary tuberculosis.
Evans SA; Colville A; Evans AJ; Crisp AJ; Johnston ID
Thorax; 1996 Dec; 51(12):1248-52. PubMed ID: 8994524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]